Table 1 Relationship between galectin-3 and CD34 expression and clinicopatholo gical features of 165 patients with hepatocellular carcinoma

All cases

165

30 (18.2%)

135 (81.8%)

35.80 × 20.82

0-77

Age (years)

0.146

0.952

<50

93

20 (21.5%)

73 (78.5%)

34.64 × 20.83

1-77

?50

72

10 (13.9%)

62 (86.1%)

37.28 × 20.85

0-76

Sex

0.353

0.926

Male

133

23 (17.3%)

110 (82.7%)

36.63 × 20.72

0-77

Female

32

7 (21.9%)

25 (78.1%)

32.33 × 21.21

1-74

Tumor size(cm)

0.393

0.103

<5

67

11 (16.4%)

56 (83.6%)

37.50 × 19.45

0-77

?5

98

19 (19.4%)

79 (80.6%)

34.63 × 21.72

2-76

Histological differentiation

0.993

0.217

Good

41

7 (17.1%)

34 (82.9%)

39.89 × 21.51

3-77

Moderate

95

17 (17.9%)

78 (82.1%)

33.43 × 19.48

0-75

Poor

29

6 (20.7%)

23 (79.3%)

37.74 × 24.05

7-76

Liver cirrhosis

0.361

0.621

No

27

6 (22.2%)

21 (77.8%)

37.86 × 21.43

11-77

Yes

138

24 (17.4%)

114 (82.6%)

35.39 × 20.75

0-76

HBsAg

0.627

0.139

Negative

17

3 (17.6%)

14 (82.4%)

30.61 × 18.38

1-76

Positive

148

27 (18.2%)

121 (81.8%)

36.39 × 21.06

0-77

Serum alpha fetoprotein

<0.01

0.843

<25 μg/L

47

20 (42.6%)

27 (57.4%)

39.61 × 20.62

0-77

?25 μg/L

118

10 (8.5%)

108 (91.5%)

34.27 × 20.79

1-76

Distant metastasis

0.128

0.252

No

152

30 (19.7%)

122 (80.2%)

35.38 × 20.55

0-77

Yes

13

0 (0%)

13 (100%)

40.60 × 24.15

10-76

Presence of intrahepatic metastasis

0.254

0.82

No

138

23 (16.7%)

115 (83.3%)

34.97 × 20.73

0-77

Yes

27

7 (25.9%)

20 (74.1%)

40.03 × 21.14

3-75

Recurrence

0.999

0.256

No

154

28 (18.2%)

126 (81.8%)

35.62 × 20.53

0-77

Yes

11

2 (18.2%)

9 (81.8%)

38.21 × 25.54

3-76